News Releases

Year

09 Sep '20

Repare Therapeutics to Participate at Morgan Stanley Annual Global Healthcare Conference

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Sep. 9, 2020-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced

13 Aug '20

Repare Therapeutics Reports Second Quarter 2020 Financial Results and Operational Highlights

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Aug. 13, 2020-- Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today reported financial results

29 Jul '20

Repare Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of RP-3500

- RP-3500 is a potent and selective oral small molecule inhibitor of ATR being developed for the treatment of solid tumors with selected genomic alterations - - Multi-center trial will evaluate RP-3500 as a monotherapy and in combination with Pfizer’s PARP inhibitor, talazoparib (Talzenna®) -

23 Jun '20

Repare Therapeutics Announces Closing of Upsized Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Jun. 23, 2020-- Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the closing of its previously

18 Jun '20

Repare Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass. & MONTRÉAL --(BUSINESS WIRE)--Jun. 18, 2020-- Repare Therapeutics Inc. (Nasdaq: RPTX), a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics, today announced the pricing of its upsized

26 May '20

Repare Therapeutics Announces Multi-Target Discovery Collaboration with Bristol Myers Squibb

Bristol Myers Squibb to leverage Repare’s proprietary SNIPRx® synthetic lethal discovery platform to identify multiple oncology drug candidates $65 million upfront payment including $15 million in equity investment Repare Therapeutics eligible to receive development, regulatory and commercial